MedTrace Logo

Blood Pressure and Central Vascular Stiffness in Obese Children. Relationship to Metabolic Disturbances and Subclinical Cardiovascular Damage. Effect of Weight Reduction

NCT01310088 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2011-03-11

No results posted yet for this study

Summary

The global epidemic of obesity in childhood continues to evolve and threaten future health and life expectancy primarily due to the increased incidence of cardiovascular disease. Obesity is strongly related to high blood pressure (hypertension) and both conditions pose a risk for target organ damage, which can follow a subject from childhood into adult life. The AORTA study will investigate central hemodynamics and organ damage in 100 obese children and adolescents in order to gain insight to the complex interplay of hypertension, obesity and subclinical damage in order to intensify more precise prevention, thereby reducing the future development of cardiovascular disease.

Conditions

  • Central Blood Pressure
  • Obesity
  • Subclinical Organ Damage
  • Children
  • Adolescent

Interventions

BEHAVIORAL

Lifestyle intervention

Treatment protocol. The Children's Obesity Clinic Department of Paediatrics Holbaek Hospital, University of Copenhagen Denmark

Sponsors & Collaborators

  • Zealand University Hospital

    lead OTHER

Principal Investigators

  • Kristian Hvidt, MD · Division of Cardiology, Department of Medicine, Holbaek Hospital, University of Copenhagen, Denmark

  • Hans Ibsen, DMSc, MD · Division of Cardiology, Department of Medicine, Holbaek Hospital, University of Copenhagen

  • Jens-Christian Holm, PhD, MD · The Children's Obesity Clinic, Department of Paediatrics, Holbaek Hospital, University of Copenhagen

  • Michael Hecht Olsen, DMSc, PhD, MD · Division of Cardiology, Department of Medicine, Glostrup Hospital, University of Copenhagen

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2013-06-30
Completion
2013-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01310088 on ClinicalTrials.gov